Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

13:53 MIN

CIDP
GBS
MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF

Incidence of GBS and CIDP Following Influenza Vaccination

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

25:18 MIN

CIDP
GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF

IgG Levels and Wear Off Reflect Administration and Outcome

Carol L. Koski, MD

GBS/CIDP Foundation International

5:51 MIN

CIDP
GBS

Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.

DOWNLOAD PDF

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN

CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF

NOW PLAYING

13:53

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

NOW PLAYING

25:18

Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

NOW PLAYING

5:51

IgG Levels and Wear Off Reflect Administration and Outcome

NOW PLAYING

14:01

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Our Experts on CIDP

VIEW ALL EXPERTS

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

CIDP
MMN

Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

CIDP

Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.

Van den Bergh, MD PhD

University Hospital Saint-Luc, Brussels, Belgium

Van den Bergh, MD PhD

University Hospital Saint-Luc, Brussels, Belgium

CIDP

Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

CIDP

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?

What are the symptoms of CIDP?

How is CIDP treated?